SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 


 

FORM 8–K/A

Amendment No. 1 to Current Report
Dated November 22, 2002

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

Date of Report (Date of Earliest Event Reported):  November 22, 2002

 

 

DEPOMED, INC.

(Exact name of registrant as specified in its charter)

 

California

 

001-13111

 

94-3229046

(State of Incorporation or Organization)

 

(Commission File Number)

 

(I.R.S. Employer Identification No.)

 

1360 O’Brien Drive, Menlo Park, California

 

94025

(Address of principal executive offices)

 

(Zip Code)

 

 

Registrant’s telephone no., including area code:

(650) 462-5900

 

 

 

NOT APPLICABLE

(Former name or former address, if changed since last report)

 

 

 

 



 

Item 7.  Financial Statements and Exhibits

 

Exhibits

10.1

Settlement and Release Agreement, dated as of November 22, 2002, between DepoMed, Inc. and Bristol-Myers Squibb Company.

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

DEPOMED, INC.

 

 

 

/s/John F. Hamilton

 

John F. Hamilton

 

Vice President - Finance and

 

Chief Financial Officer

 

 

Date:  December 23, 2002

 



 

EXHIBIT INDEX

 

Exhibit

 

10.1

Settlement and Release Agreement, dated as of November 22, 2002, between DepoMed, Inc. and Bristol-Myers Squibb Company.